{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:14:01Z","timestamp":1790723641605,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ijcard.2017.04.016","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T07:07:26Z","timestamp":1491462446000},"page":"386-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["What\u2019s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension"],"prefix":"10.1016","volume":"240","author":[{"given":"Peter J.","family":"Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roham T.","family":"Zamanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2017.04.016_bb0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00101211","article-title":"Survival in pulmonary hypertension in Spain: insights from the Spanish registry","volume":"40","author":"Escribano-Subias","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0020","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-11-31","article-title":"Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension","volume":"11","author":"Chen","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0035","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1183\/09031936.00001014","article-title":"Measuring health in pulmonary hypertension: emphasising the right end-point?","volume":"43","author":"Gomberg-Maitland","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0040","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/ijcp.12136","article-title":"Combination therapy in the management of pulmonary arterial hypertension","volume":"179","author":"Buckley","year":"2013","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","article-title":"Role of pharmacokinetics and metabolism in drug discovery and development","volume":"49","author":"Lin","year":"1997","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0075","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1542\/peds.2014-0177","article-title":"Medication adherence among pediatric patients with sickle cell disease: a systematic review","volume":"134","author":"Walsh","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0080","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","article-title":"Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials","volume":"30","author":"Benza","year":"2011","journal-title":"Int. J. Heart lung"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0085","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7326\/M14-1402","article-title":"Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension","volume":"162","author":"Langleben","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7326\/M14-2700","article-title":"Vasodilator-responsive idiopathic pulmonary arterial hypertension: evidence for a new disease?","volume":"162","author":"Brittain","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCULATIONAHA.114.013317","article-title":"Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension","volume":"131","author":"Hemnes","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2017.04.016_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.2014.876007","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"15","author":"Skoro-Sajer","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijcard.2017.04.016_bb0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.110.169748","article-title":"Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function","volume":"335","author":"Morrison","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317305004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317305004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T21:05:04Z","timestamp":1750194304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317305004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"alternative-id":["S0167527317305004"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.016","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}